Summary
C1311 is a novel therapeutic agent with potent activity against experimental colorectal cancer that has been selected for entry into clinical trial. The compound has previously been shown to have DNA-binding properties and to inhibit the catalytic activity of topoisomerase II. In this study, cellular uptake and mechanisms by which C1311 interacts with DNA and exerts cytotoxic effects in intact colon carcinoma cells were investigated. The HT29 colon cancer cell line was chosen to follow cellular distribution of C1311 over a time course of 24 h at drug concentrations that just inhibited cell proliferation by 50% or 100%. Nuclear uptake of C1311 and co-localization with lysosomal or mitochondrial dyes was examined by fluorescence microscopy and effects on these cellular compartments were determined by measurement of acid phosphatase levels, rhodamine 123 release or DNA-binding behaviour. The strength and mode of DNA binding was established by thermal melting stabilization, direct titration and viscometric studies of host duplex length. The onset of apoptosis was followed using a TUNEL assay and DNA-fragmentation to determine a causal relationship of cell death. Growth inhibition of HT29 cells by C1311 was concomitant with rapid drug accumulation in nuclei and in this context we showed that the compound binds to duplex DNA by intercalation, with likely A/T sequence-preferential binding. Drug uptake was also seen in lysosomes, leading to lysosomal rupture and a marked increase of acid phosphatase activity 8 h after exposure to C1311 concentrations that effect total growth inhibition. Moreover, at these concentrations lysosomal swelling and breakdown preceded apoptosis, which was not evident up to 24 h after exposure to drug. Thus, the lysosomotropic effect of C1311 appears to be a novel feature of this anticancer agent. As it is unlikely that C1311-induced DNA damage alone would be sufficient for cytotoxic activity, lysosomal rupture may be a critical component for therapeutic efficacy.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Agbandje, M, Jenkins, TC & Neidle, S (1992). Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. J Med Chem 35: 1418–1429.
Allison, AC (1974). Lysosomes in cancer cells. J Clin Pathol 27: 43–50.
Augustin, E, Wheatley, DN, Lamb, J & Konopa, J (1996). Imidazoacridinones arrest cell cycle progression in G2 phase of L1210 cells. Cancer Chemother Pharmacol 38: 39–44.
Bailly, C, Pommery, N, Houssin, R & Henichart, J-P (1989). Design, synthesis, DNA binding, and biological activity of a series of dna minor groove-binding intercalating drugs. J Pharm Sci 78: 910–917.
Beckwith, M, Urba, WJ & Longo, DL (1993). Growth inhibition of human lymphoma cell lines by the marine products, dolastatins 10 and 15. J Natl Cancer Inst 85: 483–488.
Berger, B, Marquardt, H & Westendorf, J (1996). Pharmacological and toxicological aspects of new imidazoacridinone antitumor agents. Cancer Res 56: 2094–2104.
Boyer, MJ & Tannock, IF (1993). Lysosomes, lysosomal enzymes and cancer. Advances in Cancer Research 60: 269–291.
Burger, AM, Kaur, G, Alley, MC, Supko, JG, Malspeis, L, Greever, MR & Sausville, EA (1995). Tyrphostin AG17 [(3,5-Di-tert-butyl-4-hydroxybenzylidene)-malononitrile], inhibits cell growth by disrupting mitochondria. Cancer Res 55: 2794–2799.
Burger, AM, Double, JA, Konopa, J & Bibby, MC (1996). Preclinical evaluation of novel imidazoacridinone derivatives with potent activity against experimental colorectal cancer. Br J Cancer 74: 1369–1374.
Chaires, JB, Dattagupta, N & Crothers, DM (1982). Studies on interaction of anthracycline antibiotics and deoxyribonucleic acid: equilibrium binding studies on interaction of daunomycin with deoxyribonucleic acid. Biochemistry 21: 3933–3940.
Cheng, CC & Cheng, RKY (1989). The design, synthesis and development of a new class of potent antineoplastic anthraquinones. In:Progress in Medicinal Chemistry, Ellis GP, West GB Elsevier: New York 88–113.
Cholody, WM, Martelli, S, Lukowicz, J & Konopa, J (1990). 5-[(Aminoalkyl)amino]imidazo4,5,1 de]acridin-6-ones as a novel class of antineoplastic agents. Synthesis and biological activity. J Med Chem 33: 49–52.
Cholody, WM, Martelli, S & Konopa, J (1992). Chromophore-modified antineoplastic imidazoacridinones. Synthesis and activity against murine leukemias. J Med Chem 35: 378–382.
Engelke, K, Krapcho, P & Hacker, M (1997). The intracellular distribution of the 9-aza-anthrapyrazole compounds is regulated by the side-chain terminal amines. Proc Am Assoc Cancer Res 38: 601
Firestone, RA, Pisano, JM & Bonney, RJ (1979). Lysosomotropic agents. 1. Synthesis and cytotoxic action of lysosomotropic detergents. J Med Chem 22: 1130–1133.
Green, DR & Reed, JC (1998). Mitochondria and apoptosis. Science 281: 1309–1312.
Haq, I, Ladbury, JE, Chowdhry, BZ, Jenkins, TC & Chaires, JB (1997). Specific binding of Hoechst 33258 to the d(CGCAAATTTGCG)2 duplex: calorimetric and spectroscopic studies. J Mol Biol 271: 244–257.
Hickman, JA (1992). Apoptosis induced by anticancer drugs. Cancer Metastas Rev 11: 121–139.
Jenkins, TC (1997). Optical absorbance and fluorescence techniques for measuring DNA–drug interactions. In:Methods in Molecular Biology, Vol. 90, Drug–DNA Interaction Protocols, Fox URFHumana Press: Totawa, NJ 195–218.
Konopa, J & Skladanowski, A (1987). Anthracyclines and anthracenediones induce covalent interstrand DNA crosslinking in tumor cells. In:Recent Advances Chemotherapy, Ishigami J University of Tokyo Press: Tokyo 663–634.
Kusnierczyk, H, Cholody, WM, Paradziej-Lukowicz, J, Radzikowski, C & Konopa, J (1994). Experimental antitumor activity and toxicity of the selected triazolo- and imidazoacridinones. Arch Immun Ther Experim 42: 415–423.
Lamb, J & Wheatley, DN (1996). Cell killing by the novel imidazoacridinone antineoplastic agent, C-1311, is inhibited at high concentrations coincident with dose-differentiated cell cycle perturbation. Br J Cancer 74: 1359–1368.
Loontiens, FG, Regenfuss, P, Zechel, A, Dumortier, L & Clegg, RM (1990). Binding characteristics of Hoechst 33258 with calf thymus DNA, poly[d(A-T)], and d(CGCGAATTCGCG): multiple stoichiometries and determination of tight binding with a wide spectrum of site affinities. Biochemistry 29: 9029–9039.
Majno, G & Joris, I (1995). Apoptosis, oncosis, and necrosis – an overview of cell death. Am J Pathol 146: 3–15.
McConnaughie, AW & Jenkins, TC (1995). Novel acridine-triazenes as prototype combilexins: synthesis, DNA binding, and biological activity. J Med Chem 38: 3488–3501.
McGhee, JD & Von Hippel, PH (1974). Theoretical aspects of DNA–protein interactions: cooperative and non-cooperative binding of large ligands to a one-dimensional heterogeneous lattice. J Mol Biol 86: 469–489.
Nicholson, KM, Bibby, MC & Phillips, RM (1997). Influence of drug exposure parameters on the activity of paclitaxel in multicellular spheroids. Eur J Cancer 33: 1291–1298.
Overgaard, J (1977). Effect of hyperthermia on malignant cells in vivo. Cancer 39: 2637–2646.
Pilch, DS, Waring, MJ, Sun, J-S, Rougee, M, Nguyen, C-H, Bisagni, E, Garestier, T & Helene, C (1993). Characterization of a triple helix-specific ligand. J Mol Biol 232: 926–946.
Quintana, JR, Lipanov, AA & Dickerson, RE (1991). Low-temperature crystallographic analyses of the binding of Hoechst 33258 to the double-helical DNA dodecamer CGCGAATTCGCG . Biochemistry 30: 10294–10306.
Simon, S, Roy, D & Schindler, M (1994). Intracellular pH and the control of multidrug resistance. Proc Natl Acad Sci USA 91: 1128–1132.
Skladanowski, A, Plisov, SY, Konopa, J & Larsen, AK (1996). Inhibition of DNA topoisomerase II by imidazoacridinones, new antineoplastic agents with strong activity against solid tumors. Mol Pharmacol 49: 772–780.
Suh, D & Chaires, JB (1995). Criteria for the mode of binding of DNA binding agents. Bioorg & Med Chem 3: 723–728.
Vega, MC, Garcia-Saez, I, Aymami, J, Eritja, T, Van der Marel, GA, van Boom, JH, Rich, A & Coll, M (1994). Three-dimensional crystal structure of the A-tract DNA dodecamer d(CGCAAATTTGCG)2 complexed with the minor groove-binding drug Hoechst 33258. Eur J Biochem 222: 721–726.
Yang, J, Liu, X, Bhalla, K, Kim, NC, Ibrado, AM, Cai, J, Peng, TI, Jones, DP & Wang, X (1997). Prevention of apoptosis by bcl-2: release of cytochrome c from mitochondria blocked. Science 275: 1129–1132.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Burger, A., Jenkins, T., Double, J. et al. Cellular uptake, cytotoxicity and DNA-binding studies of the novel imidazoacridinone antineoplastic agent C1311. Br J Cancer 81, 367–375 (1999). https://doi.org/10.1038/sj.bjc.6690702
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6690702
Keywords
This article is cited by
-
Physicochemical interaction of antitumor acridinone derivatives with DNA in view of QSAR studies
Medicinal Chemistry Research (2011)
-
Cell growth inhibition, G2M cell cycle arrest, and apoptosis induced by the novel compound Alternol in human gastric carcinoma cell line MGC803
Investigational New Drugs (2007)
-
Sequential induction of mitotic catastrophe followed by apoptosis in human leukemia MOLT4 cells by imidazoacridinone C-1311
Apoptosis (2007)
-
Staurosporine-induced apoptosis and hydrogen peroxide-induced necrosis in two human breast cell lines
British Journal of Cancer (2003)
-
The autophagosomal–lysosomal compartment in programmed cell death
Cell Death & Differentiation (2001)